The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling

Benjamin Verret; Michele Bottosso; Sofia Hervais; Barbara Pistilli

doi:10.3390/cancers14174203

The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling

Benjamin Verret, Michele Bottosso, Sofia Hervais, Barbara Pistilli

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

5 Citations (Scopus)

Résumé

The past decade was marked by several important studies deciphering the molecular landscape of metastatic breast cancer. Although the initial goal of these studies was to find driver oncogenic events to explain cancer progression and metastatic spreading, they have also permitted the identification of several molecular alterations associated with treatment response or resistance. Herein, we review validated (PI3KCA, ESR1, MSI, NTRK translocation) and emergent molecular biomarkers (ERBB2, AKT, PTEN, HRR gene, CD274 amplification RB1, NF1, mutational process) in metastatic breast cancer, on the bases of the largest molecular profiling studies. These biomarkers will be classed according the level of evidence and, if possible, the ESCAT (ESMO) classification. Finally, we will provide some perspective on development in clinical practice for the main biomarkers.

langue originale	Anglais
Numéro d'article	4203
journal	Cancers
Volume	14
Numéro de publication	17
Les DOIs	https://doi.org/10.3390/cancers14174203
état	Publié - 1 sept. 2022

Accès au document

10.3390/cancers14174203

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{2e1f5a8ab85f4d859cefb7c3027c876a,

title = "The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling",

abstract = "The past decade was marked by several important studies deciphering the molecular landscape of metastatic breast cancer. Although the initial goal of these studies was to find driver oncogenic events to explain cancer progression and metastatic spreading, they have also permitted the identification of several molecular alterations associated with treatment response or resistance. Herein, we review validated (PI3KCA, ESR1, MSI, NTRK translocation) and emergent molecular biomarkers (ERBB2, AKT, PTEN, HRR gene, CD274 amplification RB1, NF1, mutational process) in metastatic breast cancer, on the bases of the largest molecular profiling studies. These biomarkers will be classed according the level of evidence and, if possible, the ESCAT (ESMO) classification. Finally, we will provide some perspective on development in clinical practice for the main biomarkers.",

keywords = "biomarker, metastatic breast cancer, molecular biology, molecular profilig, precision medicine, targeted therapy",

author = "Benjamin Verret and Michele Bottosso and Sofia Hervais and Barbara Pistilli",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = sep,

day = "1",

doi = "10.3390/cancers14174203",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

number = "17",

}

TY - JOUR

T1 - The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer

T2 - The Contribution of Molecular Profiling

AU - Verret, Benjamin

AU - Bottosso, Michele

AU - Hervais, Sofia

AU - Pistilli, Barbara

PY - 2022/9/1

Y1 - 2022/9/1

N2 - The past decade was marked by several important studies deciphering the molecular landscape of metastatic breast cancer. Although the initial goal of these studies was to find driver oncogenic events to explain cancer progression and metastatic spreading, they have also permitted the identification of several molecular alterations associated with treatment response or resistance. Herein, we review validated (PI3KCA, ESR1, MSI, NTRK translocation) and emergent molecular biomarkers (ERBB2, AKT, PTEN, HRR gene, CD274 amplification RB1, NF1, mutational process) in metastatic breast cancer, on the bases of the largest molecular profiling studies. These biomarkers will be classed according the level of evidence and, if possible, the ESCAT (ESMO) classification. Finally, we will provide some perspective on development in clinical practice for the main biomarkers.

AB - The past decade was marked by several important studies deciphering the molecular landscape of metastatic breast cancer. Although the initial goal of these studies was to find driver oncogenic events to explain cancer progression and metastatic spreading, they have also permitted the identification of several molecular alterations associated with treatment response or resistance. Herein, we review validated (PI3KCA, ESR1, MSI, NTRK translocation) and emergent molecular biomarkers (ERBB2, AKT, PTEN, HRR gene, CD274 amplification RB1, NF1, mutational process) in metastatic breast cancer, on the bases of the largest molecular profiling studies. These biomarkers will be classed according the level of evidence and, if possible, the ESCAT (ESMO) classification. Finally, we will provide some perspective on development in clinical practice for the main biomarkers.

KW - biomarker

KW - metastatic breast cancer

KW - molecular biology

KW - molecular profilig

KW - precision medicine

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85137791856&partnerID=8YFLogxK

U2 - 10.3390/cancers14174203

DO - 10.3390/cancers14174203

M3 - Review article

AN - SCOPUS:85137791856

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 17

M1 - 4203

ER -